Cargando…
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti–PD-1 response in NSCLC
Targeting PD-1/PD-L1 is only effective in ∼20% of lung cancer patients, but determinants of this response are poorly defined. We previously observed differential responses of two murine K-Ras–mutant lung cancer cell lines to anti–PD-1 therapy: CMT167 tumors were eliminated, whereas Lewis Lung Carcin...
Autores principales: | Bullock, Bonnie L, Kimball, Abigail K, Poczobutt, Joanna M, Neuwelt, Alexander J, Li, Howard Y, Johnson, Amber M, Kwak, Jeff W, Kleczko, Emily K, Kaspar, Rachael E, Wagner, Emily K, Hopp, Katharina, Schenk, Erin L, Weiser-Evans, Mary CM, Clambey, Eric T, Nemenoff, Raphael A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Life Science Alliance LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537751/ https://www.ncbi.nlm.nih.gov/pubmed/31133614 http://dx.doi.org/10.26508/lsa.201900328 |
Ejemplares similares
-
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms
por: Neuwelt, Alexander J, et al.
Publicado: (2020) -
Upregulation of complement proteins in lung cancer cells mediates tumor progression
por: Kleczko, Emily K., et al.
Publicado: (2023) -
Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer
por: Kleczko, Emily K., et al.
Publicado: (2019) -
CD8(+) T cells modulate autosomal dominant polycystic kidney disease progression
por: Kleczko, Emily K., et al.
Publicado: (2018) -
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
por: Kleczko, Emily K., et al.
Publicado: (2023)